Human synovial mast cells: II. Heterogeneity of the pharmacologic effects of antiinflammatory and immunosuppressive drugs

Arthritis and Rheumatism

Volumn 40, Issue 3, 1997, Pages 469-478

  De Paulis, Amato ^a   Ciccarelli, Anna ^a   Marinò, Isabella ^a   De Crescenzo, Gennaro ^a   Marinò, Domenico ^a   Marone, Gianni ^a,b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DERIVATIVE; ANTIINFLAMMATORY AGENT; CYCLOSPORIN A; CYCLOSPORIN H; DICLOFENAC; HISTAMINE; IMMUNOGLOBULIN E ANTIBODY; IMMUNOSUPPRESSIVE AGENT; LEUKOTRIENE C4; NIMESULIDE; PIROXICAM; PROSTAGLANDIN D2; RAPAMYCIN; SUBSTANCE P; TACROLIMUS; TRYPTASE;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; HISTAMINE RELEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; INFLAMMATION; MAST CELL; PRIORITY JOURNAL; SYNOVIUM;

EID: 0030988026     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.1780400313     Document Type: Article

References (56)

1. Godfrey HP, Ilardi C, Engber W, Graziano FM: Quantitation of human synovial mast cells in rheumatoid arthritis and other rheumatic diseases. Arthritis Rheum 27:852-856, 1984
2. Malone DG, Irani A-M, Schwartz LB, Barrett KE, Metcalfe DD: Mast cell numbers and histamine levels in synovial fluids from patients with diverse arthritides. Arthritis Rheum 29:956-963, 1986
3. Gruber B: Activation of rheumatoid synovial mast cells: role of IgE-associated antiglobulins. Monogr Allergy 26:120-134, 1989
4. Arnason JA, Malone DG: Role of mast cells in arthritis. In, Human Basophils and Mast Cells: Clinical Aspects. Edited by G Marone. Basel, Karger, 1995
5. Gruber B, Poznansky M, Boss E, Partin J, Gorevic P, Kaplan AP: Characterization and functional studies of rheumatoid synovial mast cells: activation by secretagogues, anti-IgE, and a histamine-releasing lymphokine. Arthritis Rheum 29:944-955, 1986
6. Kopicky-Burd JA, Kagey-Sobotka A, Peters SP, Dvorak AM, Lennox DW, Lichtenstein LM, Wigley FM: Characterization of human synovial mast cells. J Rheumatol 15:1326-1333, 1988
7. Bridges AJ, Malone DG, Jicinsky J, Chen M, Ory P, Engber W, Graziano FM: Human synovial mast cell involvement in rheumatoid arthritis and osteoarthritis: relationship to disease type, clinical activity, and antirheumatic therapy. Arthritis Rheum 34:1116-1124, 1991
8. Verbsky JW, McAllister PK, Malone DG: Demonstration of mast cell activation and histamine release in human synovial explants following exposure to calcium ionophore A23187, compound 48/80, and rabbit IgG anti-human IgE, but not morphine sulfate. Inflamm Res 45:35-41, 1996
9. De Paulis A, Marinò I, Ciccarelli A, de Crescenzo G, Concardi M, Verga L, Arbustini E, Marone G: Human synovial mast cells. I. Ultrastructure in situ and in vitro immunologic characterization. Arthritis Rheum 39:1222-1233, 1996
10. + cells. J Immunol 146:2374-2381, 1991
11. Patella V, Marinò I, Lampärter B, Arbustini E, Adt M, Marone G: Human heart mast cells: isolation, purification, and immunologic characterization. J Immunol 154:2855-2865, 1995
12. Siraganian RP: An automated continuous-flow system for the extraction and fluorometric analysis of histamine. Anal Biochem 57:383-394, 1974
13. Patella V, Casolaro V, Ciccarelli A, Pettit GR, Columbo M, Marone G: The antineoplastic bryostatins affect human basophits and mast cells differently. Blood 85:1272-1281, 1995
14. Stellato C, Cirillo R, de Paulis A, Casolaro V, Patella V, Mastronardi P, Mazzarella B, Marone G: Human basophil/mast cell releasability. IX. Heterogeneity of the effects of opioids on mediator release. Anesthesiology 77:932-940, 1992
15. Stellato C, de Paulis A, Cirillo R, Mastronardi P, Mazzarella B, Marone G: Heterogeneity of human mast cells and basophils in response to muscle relaxants. Anesthesiology 74:1078-1086, 1991
16. Lawrence ID, Warner JA, Cohan VL, Hubbard WC, Kagey-Sobotka A, Lichtenstein LM: Purification and characterization of human skin mast cells: evidence for human mast cell heterogeneity. J Immunol 139:3062-3069, 1987
17. Cirillo R, Triggiani M, Siri L, Ciccarelli A, Pettit GR, Condorelli M, Marone G: Cyclosporin A rapidly inhibits mediator release from human basophils presumably by interacting with cyclophilin. J Immunol 144:3891-3897, 1990
18. Schefler WC: Statistics for Health Professionals. Reading, MA, Addison-Wesley Publishing Company, 1984
19. Insel PA: Analgesic-antipyretic and antiinflammatory agents and drugs employed in the treatment of gout. In, The Pharmacological Basis of Therapeutics. Ninth edition. Edited by JG Haedman, LE Limbird, PB Molinoff, RW Ruddon, A Goodman Gilman. New York, McGraw-Hill Companies, 1996
20. Brooks PM, Day RO: Nonsteroidal antiinflammatory drugs - differences and similarities. N Engl J Med 324:1716-1725, 1991
21. Swingle KF, Moore GGI, Grant TJ: 4-Nitro-2-phenoxymethane sulfonanilide (R-805): a chemically novel anti-inflammatory agent. Arch Int Pharmacodyn Ther 222:132-139, 1976
22. Ward A, Brogden RN: Nimesulide: a preliminary review of its pharmacological properties and therapeutic efficacy in inflammation and pain states. Drugs 36:732-753, 1988
23. Fowler PD, Dawes PT, John VA, Shotton PA: Plasma and synovial fluid concentrations of diclofenac sodium and its hydroxylated metabolites during once-daily administration of a 100 mg slow-release formulation. Eur J Clin Pharmacol 31:469-472, 1986
24. Richardson CJ, Blocka KLN, Ross SG, Verbeeck RK: Piroxicam and 5′-hydroxypiroxicam kinetics following multiple dose administration of piroxicam. Eur J Clin Pharmacol 32:89-91, 1987
25. Hamberg M: Inhibition of prostaglandin synthesis in man. Biochem Biophys Res Commun 49:720-726, 1972
26. Swingle KF, Moore GGI: Preclinical pharmacological studies with nimesulide. Drugs Exp Clin Res 10:587-597, 1984
27. Undem BJ, Peachell PT, Lichtenstein LM: Isoproterenol-induced inhibition of immunoglobulin E-mediated release of histamine and arachidonic acid metabolites from the human lung mast cell. J Pharmacol Exp Ther 247:209-217, 1988
28. Wittenberg RH, Willburger RE, Kleemeyer KS, Peskar BA: In vitro release of prostaglandins and leukotrienes from synovial tissue, cartilage, and bone in degenerative joint diseases. Arthritis Rheum 36:1444-1450, 1993
29. Mican JM, Metcalfe DD: Arthritis and mast cell activation. J Allergy Clin Immunol 86:677-683, 1990
30. Weinblatt ME, Coblyn JS, Fraser PA, Anderson RJ, Spragg J, Trentham DE, Austen KF: Cyclosporin A treatment of refractory rheumatoid arthritis. Arthritis Rheum 30:11-17, 1987
31. Førre Ø, and the Norwegian Arthritis Study Group: Radiologic evidence of disease modification in rheumatoid arthritis patients treated with cyclosporine: results of a 48-week multicenter study comparing low-dose cyclosporine with placebo. Arthritis Rheum 37:1506-1512, 1994
32. Pasero G, Priolo F, Marubini E, Fantini F, Ferraccioli G, Magaro M, Marcolongo R, Oriente P, Pipitone V, Portioli I, Tirri G, Trotta F, Della Casa-Alberighi O: Slow progression of joint damage in early rheumatoid arthritis treated with cyclosporin A. Arthritis Rheum 39:1006-1015, 1996
33. Gupta AK, Matteson EL, Ellis CN, Ho VC, Tellner DC, Voorhees JJ, McCune J: Cyclosporine in the treatment of psoriatic arthritis. Arch Dermatol 125:507-510, 1989
34. LeGrue SJ, Turner R, Weisbrodt N, Dedman JR: Does the binding of cyclosporine to calmodulin result in immunosuppression? Science 234:68-71, 1986
35. Keown PA, Stiller CR, Stawecki M, McMichael J, Howson W: Pharmacokinetics and interactions of cyclosporin. In, Cyclosporin in Autoimmune Diseases. Edited by R Schindler. New York, Springer-Verlag, 1985
36. Casolaro V, Spadaro G, Patella V, Marone G: In vivo characterization of the anti-inflammatory effect of cyclosporin A on human basophils. J Immunol 151:5563-5573, 1993
37. Sawada S, Suzuki G, Kawase Y, Takaku F: Novel immunosuppressive agent, FK-506: in vitro effects on cloned T cell activation. J Immunol 139:1797-1803, 1987
38. Wicker LS, Boltz RC Jr, Matt V, Nichols EA, Peterson LB, Sigal NH: Suppression of B cell activation by cyclosporin A, FK-506 and rapamycin. Lur J Immunol 20:2277-2283, 1990
39. Findlay JA, Radics L: On the chemistry and high field nuclear magnetic resonance spectroscopy of rapamycin. Can J Chem 58:579-590, 1980
40. Dumont FJ, Staruch MJ, Koprak SL, Melino MR, Sigal NH: Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin. J Immunol 144:251-258, 1990
41. Bierer BE, Mattila PS, Standaert RF, Herzenberg LA, Burakoff SJ, Crabtree G. Schreiber SL: Two distinct signal transmission pathways in T lymphocytes are inhibited by complexes formed between an immunophilin and either FK506 or rapamycin. Proc Natl Acad Sci U S A 87:9231-9235, 1990
42. Inamura N, Hashimoto M, Nakahara K, Aoki H, Yamaguchi I, Kohsaka M: Immunosuppressive effect of FK506 on collagen-induced arthritis in rats. Clin Immunol Immunopathol 46:82-90, 1988
43. Carlson RP, Hartman DA, Tomchek LA, Walter TL, Lugay JR, Calhoun W, Sehgal SN, Chang JY: Rapamycin, a potential disease-modifying antiarthritic drug. J Pharmacol Exp Ther 266:1125-1138, 1993
44. Ochiai T, Gunji Y, Sakamoto K, Suzuki T, Isegawa N, Asano T, Isono K: Optimal serum trough levels of FK506 in renal allotransplantation of the beagle dog. Transplantation 48:189-193, 1989
45. Weinblatt ME, Coblyn JS, Fox DA, Fraser PA, Holdsworth DE, Glass DN, Trentham DE: Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 312:818-822, 1985
46. Cronstein BN, Naime D, Ostad E: The antiinflammatory mechanism of methotrexate: increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J Clin Invest 92:2675-2682, 1993
47. Marone G, Cirillo R, Genovese A, Marino O, Quattrin S: Human basophil/mast cell releasability. VII. Heterogeneity of the effect of adenosine on mediator secretion. Life Sci 45:1745-1754, 1989
48. Levine JD, Moskowitz MA, Basbaum AI: The contribution of neurogenic inflammation in experimental arthritis. J Immunol 135:843s-847s, 1985
49. Lotz M, Carson DA, Vaughan JH: Substance P activation of rheumatoid synoviocytes: neural pathway in pathogenesis of arthritis. Science 235:893-895, 1987
50. Casolaro V, Meliota S, Marino O, Patella V, de Paulis A, Guidi G, Marone G: Nimesulide, a sulfonanilide nonsteroidal antiinflammatory drug, inhibits mediator release from human basophils and mast cells. J Pharmacol Exp Ther 267:1375-1385, 1993
51. Malone DG, Vikingsson A, Seebruch JS, Verbsky JW, Dolan PW: In vivo effects of nonsteroidal antiinflammatory drugs on rat skin and synovial mast cell-induced vasopermeability. Arthritis Rheum 34:164-170, 1991
52. Clipstone NA, Crabtree GR: Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation. Nature 357:695-697, 1992
53. De Paulis A, Ciccarelli A, de Crescenzo G, Cirillo R, Patella V, Marone G: Cyclosporin H is a potent and selective competitive antagonist of human basophil activation by FMLP. J Allergy Clin Immunol 98:152-164, 1996
54. Fruman DA, Bierer BE, Benes JE, Burakoff SJ, Austen KF, Katz HR: The complex of FK506-binding protein 12 and FK506 inhibits calcineurin phosphatase activity and IgE activation-induced cytokine transcripts, but not exocytosis, in mouse mast cells. J Immunol 154:1846-1851, 1995
55. Brown EJ, Beal PA, Keith CT, Chen J, Shin TB, Schreiber SL: Control of p70 S6 kinase by kinase activity of FRAP in vivo. Nature 377:441-446, 1995
56. Peachell PT, Columbo M, Kagey-Sobotka A, Lichtenstein LM, Marone G: Adenosine potentiates mediator release from human lung mast cells. Am Rev Respir Dis 138:1143-1151, 1988